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A method for As determination in sulfur-containing active pharmaceutical ingredients (SC-APIs) by direct solid sampling graphite 
furnace atomic absorption spectrometry (DSS-GF AAS) was developed. The proposed method was successfully applied to three 
SC-APIs (hydrochlorothiazide, furosemide and sulfadiazine). Palladium was used as chemical modifier as well as hydrogen 
during the pyrolysis allowing the direct determination of As in the SC-APIs without interferences caused by gaseous sulfur 
species. Sample masses (hydrochlorothiazide) from 0.4 to 3 mg were used and calibration with aqueous standard solutions was 
feasible. The limit of quantification was 0.033 μg g-1 and the calibration ranged from 0.1 to 1.6 ng As. Recoveries for As solutions 
added directly to the solid samples were between 95 and 103%, showing a good accuracy. The method validation highlighted its 
robustness, since variation in pyrolysis and atomization temperatures, as well as in Pd and sample masses, did not change 
significantly the results. Additional experiments showed that this method can be applied to other SC-APIs (as e.g., furosemide and 
sulfadiazine). Arsenic concentration in hydrochlorothiazide samples ranged from 0.13 to 0.48 μg g-1, while in furosemide and 
sulfadiazine samples it was from 0.49 and 0.54 μg g-1, respectively. The use of DSS-GF AAS does not require previous sample 
digestion and As could be directly determined in the solid samples providing some advantages, as lower risks of contamination 
and analyte losses, good accuracy and limits of quantification. 
Keywords: Arsenic determination; Solid sampling; Graphite furnace atomic absorption spectrometry; Elemental impurities 
determination; Toxic elements. 
 
 
Introduction  
 
The determination of elemental impurities is a critical aspect 
for the quality control of pharmaceutical products mainly 
due to their toxicity [1]. In view of the presence of some 
toxic impurities, the routine quality control of active 
pharmaceutical ingredients (APIs) by pharmaceutical 
industry is mandatory [2-4]. Moreover, some contaminants 
could decrease the stability of APIs even at ultra-trace levels 
[5]. Among these impurities, arsenic is one of the most 
relevant due to its toxicity, in special the carcinogenic effect 
[6]. Arsenic is classified as “class 1” elemental impurity 
(ICH Q3D) [7], due to the toxicological aspects and the 
likelihood of occurrence of this element in pharmaceutical 
products [7]. Therefore, arsenic should be monitored in APIs 
in order to access its contamination during the treatment.  
Hydrochlorothiazide and furosemide (Figure 1, A and B) are 
raw materials widely used in pharmaceutical industry for the 
production of diuretic and antihypertensive medicines. In the 
same way, sulfadiazine (Figure 1C) is a raw material used 
for the production of antibiotics [8]. The common feature 
among them is that all are sulfur-containing active 
pharmaceutical ingredients (SC-APIs). 
Arsenic determination has been described in many 
pharmacopoeias as United States Pharmacopoeia (USP) [2], 
European Pharmacopoeia (EP) [3] and Brazilian 
Pharmacopoeia (BP) [4]. USP and EP set the maximum 
arsenic concentration of 1.5 μg g-1 (for parenteral and oral 
exposure) in agreement with ICH Q3D [7]. On the other 
hand, for hydrochlorothiazide and furosemide, BP only 
establishes the limit to the maximum heavy metal group 
content (the sum of heavy metals content, in which As is 
included) as being 10 and 20 μg g-1 for hydrochlorothiazide  
and furosemide, respectively. For sulfadiazine, BP 
establishes a maximum content of heavy metals of 20 μg g-1 
and 2 μg g-1 of arsenic. 
  
 
Figure 1. Structure of SC-APIs: hydrochlorothiazide (A), 
furosemide (B), sulfadiazine (C). 
Inductively coupled plasma optical emission spectrometry 
(ICP-OES) and inductively coupled plasma mass 
spectrometry (ICP-MS) have been recommended for arsenic 
determination in pharmaceutical products and APIs [4,9-10]. 
Both techniques allow a rapid and accurate determination of 
As with low limits of detection (LODs, ng g-1 range) [11]. 
However, before the determination by ICP-OES or ICP-MS, 
the solubilization or digestion of sample matrix is commonly 
performed by using concentrated acids and under heating 
[4,10]. Unfortunately, this procedure generally is time 
consuming and prone to contamination and analyte losses 
[12-14]. 
On the other hand, As can also be determined by graphite 
furnace atomic absorption spectrometry (GF AAS), a well-
established technique for As determination in several types 
of samples [15-16]. However, the conventional application 
of GF AAS also involves a previous sample digestion. An 
alternative to this conventional procedure is by using direct 
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solid sampling graphite furnace atomic absorption 
spectrometry (DSS-GF AAS), that enables the direct 
determination of As in solid samples using a special device 
for sample introduction. Using DSS-GF AAS, problems 
related to unsuitable LODs or difficulties on sample 
digestion can be solved [12]. This technique has been 
applied for trace elements determination at low levels in a 
wide range of samples [17-25] taking into account the 
following features as i) it practically avoids sample 
pretreatment step, ii) low contamination risk, iii) low risk of 
analyte loss, and iv) the use of corrosive and hazardous 
chemicals is avoided. Thus, the use of DSS-GF AAS for As 
determination at low levels in pharmaceuticals could present 
advantages over the techniques based on wet digestion for 
further As determination. 
A drawback during arsenic determination when using DSS-
GF AAS for sulfur-containing matrices is the occurrence of 
spectral and chemical interferences. Thermal decomposition 
of sulfur-containing compounds often results in chemical 
species that show structured or broad-band unspecific 
background (BG) signals over a wide spectral range [26] 
bringing difficulties to the acquisition of analytical signals. 
However, the application of chemical modifiers, careful 
adjustment of heating program and the use of an efficient 
BG correction system (e.g., Zeeman effect), generally are 
able to provide suitable GF AAS measurements [18,27]. 
Hydrogen has also been proved to be effective to reduce the 
BG [20,23,28] and/or to improve the effectiveness of Pd as 
chemical modifier [29], making feasible the analysis by 
DSS-GF AAS. However, this approach was still not applied 
to the determination of As in organic SC-APIs. 
Thus, a method for direct As determination in SC-APIs by 
DSS-GF AAS is proposed in this work. Operational 
parameters were evaluated using hydrochlorothiazide 
sample and the developed method was applied to other SC-
APIs as furosemide and sulfadiazine. The influence of 
chemical modifiers (palladium and/or hydrogen) was also 
investigated as well as the possibility of instrument 
calibration using aqueous standards. Results were compared 
with those obtained by ICP-OES, ICP-MS and GF AAS, 
after digestion in closed vessels. 
Experimental 
Instrumentation and operational conditions 
Arsenic determination was carried out using a AAS ZEEnit 
60 atomic absorption spectrometer (Analytik Jena, 
Germany) equipped with a Zeeman-effect BG correction 
system (field strength 0.8 T). Transversely heated graphite 
tubes, a hollow cathode lamp for As (8 mA, 193.7 nm), a 
device for direct solid sampling (Model SSA-6Z, Analytik 
Jena) and pyrolytic coated graphite tubes (Analytik Jena, 
Part Nr. 407-152.023) were used. A spectral bandpass of 0.8 
nm was used and the analytical signals were integrated in 10 
s. Background was monitored in peak height. A 
microbalance model M2P (Sartorius Germany) with 
resolution of 1 μg was used for sample weighing.  
Argon 99.996% of purity (White Martins - Praxair, Brazil) 
was used for the instruments of ICP-OES, ICP-MS and GF 
AAS. Hydrogen (99.999%, White Martins) was used for 
DSS-GF AAS measurements.  
For comparison of the results obtained by the proposed 
method, the SC-API samples were also digested in quartz 
closed vessels under microwave radiation (Multiwave 3000, 
Anton Paar, Austria) and the digests were analyzed by ICP-
OES, ICP-MS and GF AAS.  
Arsenic determination by ICP-OES was performed using a 
Optima 4300 DV (Perkin Elmer, USA), equipped with a 
cyclonic spray chamber, a GemCone® nebulizer, and quartz 
torch with alumina injector tube (2 mm i.d.). 
Radiofrequency power was set at 1400 W and the principal, 
nebulizer and auxiliary gas flow rates were 15, 0.6 and 0.2 L 
min-1, respectively. The wavelength 188.979 nm was used 
for data acquisition (three points per peak and two points for 
BG correction). The instrument was operated using axial 
view configuration.  
The determinations by ICP-MS was performed by using an 
Elan DRC II (PerkinElmer Sciex, Canada), equipped with a 
concentric nebulizer (Meinhard Associates, USA), a 
cyclonic spray chamber and a quartz torch with a quartz 
injector tube (2 mm i.d.). Radiofrequency power was set at 
1300 W and principal, auxiliary gas and nebulizer gas flow 
rates were 15, 1.2 and 1.12 L min-1, respectively. The m/z 75 
was monitored for As. For the analysis by conventional GF 
AAS the conditions recommended by the manufacturer were 
used throughout (Analytik Jena AG, Win AAS V 3.13.0 
eng, 1998-2004, Jena, Germany). 
Samples and Reagents 
Powdered pharmaceutical grade hydrochlorothiazide 
(samples A, B, C and D) and also furosemide and 
sulfadiazine (one sample each) were purchased from 
pharmaceutical industries. Hydrochlorothiazide sample A 
was used for method development, optimization of heating 
program and the evaluation of chemical modifiers by DSS-
GF AAS. These samples were previously dried at 105 °C for 
2 h. Purified water (Milli-Q system - Millipore Corp., USA) 
was used for preparation of solutions and dilutions. The As 
reference solutions were prepared by dilution of a stock 
solution (1000 mg L-1 As in 2% HNO3, Merck). Concentrated 
HNO3 was distilled in a sub-boiling system (Milestone, 
Model duoPUR 2.01 E, Italy). All other reagents were of 
analytical grade or better (Merck, Germany). 
 
Procedures 
 
For As determination by DSS-GF AAS, solid samples were 
weighted directly on the graphite platform, followed by the 
addition of Pd solution as chemical modifier. Thus, the solid 
sample plus the chemical modifier were transferred to the 
graphite tube. Blanks were evaluated by simulating the same 
steps. Pyrolysis and atomization curves were established 
with temperatures ranging from 1000 to 1800 °C and from 
2000 to 2600 °C, respectively. The effectiveness of 
hydrogen as chemical modifier (0.5 L min-1 added as 
additional gas) was evaluated by adding during the pyrolysis 
step combined with the use of 6 μg Pd. The amount of 
chemical modifier was based on the conditions described in 
the literature [20]. Additionally, the suitable sample mass 
range (from 0.1 to 3 mg) that can be used for As 
determination was also investigated [30].  
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For As determination by ICP-OES, ICP-MS and GF AAS, 
hydrochlorothiazide samples were previously digested under 
microwave irradiation in quartz closed vessels. About 0.3 g 
of sample were transferred to the vessels and 6 mL of 
concentrated HNO3 were added. Vessels were closed, and 
the following irradiation program was applied: 10 min of 
ramp up to 1400 W, 1400 W for 20 min and 20 min at 0 W 
for cooling [31]. Afterwards, digests were diluted with water 
up to 50 mL.  
The optimized conditions for As determination in 
hydrochlorothiazide by DSS-GF AAS were also applied for 
the analysis of furosemide and sulfadiazine samples. 
 
Method validation and statistical analysis 
 
Considering that there is no available certified reference 
material for As with similar composition to 
hydrochlorothiazide, the accuracy of the proposed method 
was performed by two approaches: i) recovery tests 
performed by adding arsenic (from reference solution) to the 
solid hydrochlorothiazide sample after weighing; ii) 
comparison with other detection techniques (ICP-OES, ICP-
MS and GF AAS) after microwave-assisted digestion. The 
limit of quantification (LOQ) and the linearity (R2) of 
analytical curve were also evaluated. Robustness was 
evaluated based on the results obtained after variations in 
the pyrolysis and atomization temperatures and for the mass 
of sample and Pd. Repeatability was studied with intra-day 
and inter-day (intermediate precision) through the relative 
standard deviation (RSD) after analysis. These parameters 
were evaluated according to ICH Q2(R1) [32].  
Data were analyzed by ANOVA followed by Tukey´s test 
when suitable. Data was considered statistical different 
when p<0.05.  
 
Results and discussion 
 
Pyrolysis and atomization curves by DSS-GF AAS for As 
determination in hydrochlorothiazide  
 
In all experiments the use of Pd (6 μg) as chemical modifier 
was performed taking into account its effectiveness in the 
As determination in a wide variety of samples [20,33]. 
Preliminary studies showed the need of a cool down step 
(100 °C, 15 s) before atomization to impair further 
interference caused by matrix vapors formed during the 
pyrolysis. It is important to point out that since using 
pyrolysis temperatures of 1600 °C (50 s) the spectrometer 
was not able to set the baseline prior to the atomization, 
being mandatory the use of the cool down step. 
In initial experiments it was attempted to perform the 
pyrolysis and atomization curves for arsenic in 
hydrochlorothiazide by DSS-GF AAS. The analytical 
signals presented high baseline drifting caused by the high 
BG signal. As an example, in Figure 2A is shown that in the 
recommended pyrolysis temperature (1300 °C) for arsenic 
using Pd [34-36] the BG signal was about 1.4 (peak height) 
and an insufficiently corrected/high noise analytical signal 
was observed, probably due to the overcorrection effect. The 
application of higher pyrolysis temperatures resulted in 
lower BG signals, but the analytical signal also decreased, 
even using Pd, impairing the As determination (data not 
shown).   
Thus, due to the impossibility to obtain analytical signals 
without any overcorrection problems, tests using gaseous 
hydrogen introduced together with argon into the graphite 
tube during the pyrolysis were performed. The use of 
gaseous hydrogen was already proposed for pre-reduction of 
Pd into the graphite tube forming metallic Pd in order to 
increase its efficiency [37] and/or decrease BG signals 
[38,39]. As can be seen in Figure 2B the use of hydrogen 
decreased BG values. The background signal for As 
determination in solid hydrochlorothiazide by DSS-GF AAS 
was relatively small (< 0.1, peak height) and the analytical 
signal did not present baseline drifting and other 
overcorrection problems. Therefore, pyrolysis and 
atomization curves were established with hydrogen addition 
during the pyrolysis step.  
 
 
 
 
Figure 2: Analytical (red) and BG (blue) signals for arsenic in 
hydrochlorothiazide by DSS-GF AAS. Pyrolysis at 1300 °C and 
atomization at 2400 °C, using 6 μg Pd. A: 0.949 mg (no H2 during 
the pyrolysis step); B: 0.988 mg (0.5 L min-1 H2 during the pyrolysis 
step). 
 
The pyrolysis curve for As determination in solid 
hydrochlorothiazide by DSS-GF AAS (Figure 3) presented 
very low BG signal at temperatures higher than 1100 °C. 
The best analytical signal was obtained at 1300 °C, once that 
at higher temperatures, the analytical signals decreased and 
higher RSDs were observed. For the atomization curve 
(Figure 3) the BG signals were lower than 0.4 (peak height), 
being well corrected by the Zeeman-effect correction 
system. The analytical signals increased up to 2400 °C, 
presenting a peak shape with no overcorrection and total 
integration in 10 s (Figure 2B). For atomization 
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temperatures of 2500 and 2600 °C, the analytical signals 
presented lower precision. 
 
 
 
Figure 3: Pyrolysis and atomization curves for As in 
hydrochlorothiazide using DSS-GF AAS: analytical (red) and BG 
(blue, peak height) signals. Pyrolysis at 1300 °C and atomization at 
2400 °C. Vertical bars are the standard deviations (n = 3). 
Hydrochlorothiazide mass was 1.018 ± 0.04 mg, 6 μg Pd was used 
as chemical modifier and hydrogen 0.5 L min-1 were used during 
the pyrolysis step. 
 
Thus, 1300 and 2400 °C were selected as pyrolysis and 
atomization temperatures, respectively, for As determination 
in hydrochlorothiazide by DSS-GF AAS. These temperature 
parameters were partially in agreement with those reported 
in previous works suggesting 1300 and 2200 oC for pyrolysis 
and atomization temperatures, respectively, for As 
determination using Pd as chemical modifier [20,34-36]. 
Although no memory effects have been observed, a clean-up 
step (2600 °C) was always applied. The optimized 
conditions for As determination in hydrochlorothiazide by 
DSS-GF AAS are shown in Table 1. 
 
Sample mass range 
 
The sample mass range that could be introduced into the 
graphite tube under optimized conditions (Table 1) was 
investigated according to a work previously described in the 
literature [30]. 
The effect of sample mass (hydrochlorothiazide) on the 
analytical signal was assessed by DSS-GF AAS (Figure 4), 
and sample masses from 0.05 to 3 mg were used. Results 
show that low sample masses (from 0.05 to 0.4 mg) 
produced overestimated results, although masses higher than 
0.4 mg showed no influence on the analytical signal. The 
occurrence of underestimated signals for high samples 
masses (up to 3 mg) were not observed [30]. Moreover, 
further experiments showed that hydrochlorothiazide masses 
ranging from 0.4 mg up to 3 mg could be used without any 
interference in the analytical performance. 
 
 
Figure 4: Influence of sample mass on analytical results for 
As determination by DSS-GF AAS. Dotted lines show the 
usable mass range. 
 
Sample analysis and method validation 
 
Calibration was feasible using aqueous reference standard 
solutions. Thus, the characteristic mass for the proposed 
method by DSS-GF AAS for As was 20.17 pg (aqueous 
solution) [34]. 
The As concentrations in hydrochlorothiazide samples 
ranged from 0.13 to 0.48 μg g-1 (Table 2). The results 
obtained by the proposed method were not statistically 
different from those by ICP-MS and GF AAS after acid 
digestion. Arsenic concentrations in hydrochlorothiazide 
samples by ICP-OES were lower than the LOD (3σ, n = 10), 
impairing any comparison. 
Accuracy was also evaluated by adding As reference 
solutions to the solid hydrochlorothiazide (sample A), after 
weighing and modifier addition, corresponding to As 
concentration of 0.68, 0.96 and 1.24 μg g-1. Recoveries 
ranged from 95 to 103% (RSD below 6%). The LOQ, 
calculated using the standard deviation of 10 blank 
measurements (10 σ, n = 10), was 0.033 μg g-1. Since the 
maximum As content allowed by ICH Q3D is 1.5 μg g-1 [7], 
this LOQ was considered suitable and fit for purpose. The 
linear concentration range of the calibration curve was from 
0.1 to 1.6 ng (R2 > 0.995). The robustness of the proposed 
method was evaluated varying the pyrolysis (1200 to 1400 
°C) and atomization (2300 to 2500 °C) temperatures, the Pd 
amount (5 to 7 μg) and sample mass (0.4 to 3 mg). After 
varying all these parameters, the variation in the analytical 
results were lower than 10%. The repeatability and 
intermediate precision presented RSD below 10%. All these 
parameters were considered suitable for arsenic 
determination. 
 
Feasibility of the proposed method for As determination in 
other SC-APIs 
 
Furosemide and sulfadiazine are well known SC-APIs 
currently used in therapeutics. These molecules present 
sulfur atoms, that could lead to interferences when the As 
determination is performed by DSS-GF AAS, as previously 
discussed for hydrochlorothiazide (Figure 2). These SC-
APIs also require quality control related to elemental 
impurities/arsenic content [2-4].  
 
Drug Anal Res, 2019; v. 3, n.  01, 2-9 
 
6 
As can be seen in Figures 5A and 5B, relative high BG 
signals were observed when furosemide and sulfadiazine 
samples were analyzed by DSS-GF AAS (no H2), leading to 
insufficiently corrected/high noise analytical signals, 
probably due to the overcorrection.   
 
 
Table 1: Heating program for arsenic determination in hydrochlorothiazide by DSS-GF AAS. 
 Temperature  
(oC) 
Ramp 
(oC s-1) 
Time (s) Inert gas 
 (L min-1) 
Hydrogen 
 (L min-1) 
Drying #1 110 15 30 2 - 
Drying #2 120 15 15 2 - 
Pyrolysis #1 1300 400 20 2 0.5 
Pyrolysis #2* 100 0 15 2 - 
Auto zero 100 0 6 - - 
Atomization 2400 3000 10 - - 
Clean out 2600 3000 4 2 - 
 *Cool down step 
 
 
Table 2: Results for the determination of arsenic in hydrochlorothiazide by the proposed DSS-GF AAS method (values in g g-1, mean and 
standard deviation), and by ICP-OES, ICP-MS and GF AAS after digestion (n≥3). 
Samples DSS-GF AAS ICP-OES ICP-MS GF AAS 
Hydrochlorothiazide     
A 0.40 ± 0.03 < 0.9* 0.40 ± 0.05 0.36 ± 0.05 
B 0.13 ± 0.01 < 0.9* 0.12 ± 0.03 < 0.16** 
C 0.39 ± 0.05 < 0.9* 0.39 ± 0.06 0.35 ± 0.06 
D 0.48 ± 0.03 < 0.9* 0.45 ± 0.06 0.38 ± 0.05 
Furosemide 0.49 ± 0.04 < 0.9* 0.50 ± 0.05 0.46 ± 0.06 
Sulfadiazine 0.54 ± 0.04 < 0.9* 0.51 ± 0.06 0.52 ± 0.05 
* LOD by using ICP-OES; ** LOD by using GF AAS 
 
 
            
Figure 5: Analytical (red) and BG (blue) signals for arsenic in SC-APIs by DSS-GF AAS. Pyrolysis at 1300 °C and atomization at 2400 °C, 
using 6 μg Pd. A: 1.012 mg furosemide (no H2 during the pyrolysis step); B: 1.030 mg sulfadiazine (no H2 during the pyrolysis step); C: 1.042 
mg furosemide + 0.5 L min-1 H2 during the pyrolysis step; D: 1.023 mg sulfadiazine + 0.5 L min -1 H2 during the pyrolysis step. 
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On the other hand, when gaseous H2 was used during the 
pyrolysis step, the analytical signals for As were acquired 
without deformations and totally integrated in 10 s. In 
addition, the background signals were lower than 0.15 (peak 
height) and were totally correct (Figures 5, C and D). This 
fact supports that arsenic determination in these sulfur 
containing substances by DSS-GF AAS is possible if 
gaseous hydrogen is used during pyrolysis. 
In addition, applying the optimized conditions for arsenic 
determination in hydrochlorothiazide by DSS-GF AAS 
(Table 1 and discussion in sections 3.2 and 3.3), the arsenic 
concentration in furosemide and sulfadiazine samples were 
0.49 and 0.54 μg g-1, respectively (Table 2). As also observed 
for hydrochlorothiazide samples, the arsenic concentrations 
were not statistically different from those by ICP-MS and 
GF AAS after acid digestion and the results by ICP-OES 
were lower than the LOD. 
The proposed method by DSS-GF AAS for As 
determination in SC-APIs presented similar LOQ to those 
found in literature for other APIs using ICP-MS after sample 
digestion (MIC/wet digestion) [13,31]. However, DSS-GF 
AAS allowed the use of lower sample amounts (<3mg), 
contrarily to other methods that required previous sample 
digestion of higher sample amounts (from 80 up to 500 mg) 
[13,31]. In addition, the time-consuming sample preparation 
step and the use of concentrated reagents (i.e. HNO3, H2O2) is 
avoided. In the proposed method, the heating cycle 
(determination) was performed in less than 2 minutes (Table 
1), and if the other analytical procedures (sample weighting, 
modifier addition, etc.) are included the total time for a 
determination was only 5 minutes. In this way, sample 
preparation step is avoided and the results could be obtained 
faster using DSS-GF AAS. 
Conclusion 
The DSS-GF AAS method for As determination in SC-APIs 
was feasible. The conventional procedure involves, prior to 
determination by plasma-based techniques (ICP-OES/ICP-
MS), sample digestion using concentrated acids and at high 
temperatures, characterized as a time-consuming process. In 
this work a simple procedure by using solid sample (no 
digestion was required) by GF AAS using Pd and hydrogen 
as chemical modifiers proved to be suitable for direct As 
determination in these kind of sample, avoiding background 
overcorrection problems. 
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